Recombinetics

Recombinetics, founded in 2008, is a global leader in proprietary gene repair and gene-editing technology. The company's breakthrough scientific research and development of TALEN and CRISPR (Cas9) gene editing technologies has resulted in breakthroughs in regenerative medicine, disease research, and animal agriculture. Led by a team of expert geneticists, genome engineers, and reproductive physiologists, the company is headquartered in St. Paul, Minnesota. Recombinetics operates in the biotechnology, healthcare, and life sciences industries. The company recently secured a Series A investment on 21 August 2018. The details of the investors involved in this funding round were not disclosed. Recombinetics' focus on gene editing technologies places it at the forefront of the evolving healthcare landscape, with potential applications across various sectors including medicine, research, and agriculture.